Drug Information

Drug General Information
Drug ID
D0B1OH
Former ID
DNCL003432
Drug Name
ASB17061
Indication Atopic dermatitis [ICD9: 691.8, 692.9; ICD10:L00-L99] Phase 2 [524171]
Company
Daiichi Sankyo
Target and Pathway
Target(s) Chymase Target Info Modulator [532439]
KEGG Pathway Renin-angiotensin system
Reactome Activation of Matrix Metalloproteinases
Metabolism of Angiotensinogen to Angiotensins
WikiPathways ACE Inhibitor Pathway
Metabolism of Angiotensinogen to Angiotensins
References
Ref 524171ClinicalTrials.gov (NCT01756898) A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis. U.S. National Institutes of Health.
Ref 532439Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy. 2013 Aug;68(8):974-82.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.